title: Effects of alcoholism typology on response to naltrexone in the COMBINE study.
abstract: BACKGROUND
  This study investigated whether subgroups of alcohol-dependent patients responded differently to naltrexone versus placebo in the NIAAA COMBINE study. In particular, the A versus B and the Early Onset versus Late Onset typologies were examined. Relative to Type A alcoholics, Type B alcoholics are characterized by greater severity, earlier onset, stronger family history, more childhood risk factors (e.g., conduct disorder), and greater frequency of comorbid psychiatric and substance use disorders.
  
  
  METHODS
  COMBINE study participants were categorized as Type A or Type B using k-means cluster analysis and variables from 5 domains that have been shown to replicate the original Babor typology efficiently. Early Onset was defined as alcohol dependence beginning before age 25. For the planned analyses, the sample was reduced to the 618 participants receiving naltrexone alone or placebo, either with medical management (MM) alone or with MM plus the Combined Behavioral Intervention (CBI). The a priori primary outcome was percent heavy drinking days during treatment in the groups receiving MM without CBI.
  
  
  RESULTS
  Among those receiving MM without CBI, Type A alcoholics had better drinking outcomes with naltrexone than placebo, whereas medication condition did not influence outcomes significantly in the Type Bs. Age of onset was not significantly related to outcome. For those receiving CBI, no significant effects were found for either typology.
  
  
  CONCLUSIONS
  In this sample, the beneficial effects of opioid antagonism were limited to Type A alcoholics receiving treatment in a MM model. Future studies should investigate the relationship between clinically relevant genotypes, phenotypes such as typologies, and treatment response. More work is also needed to develop practical algorithms for phenotypic assignment.
authors.affiliation: University of New Mexico Health Sciences Center, Department of Psychiatry and University of New Mexico Center on Alcoholism, Substance Abuse, and Addictions, Albuquerque, New Mexico. mbogenschutz@salud.unm.edu
authors.forename: Michael P
authors.initials: MP
authors.lastname: Bogenschutz
authors.forename: J
authors.initials: J
authors.lastname: Scott Tonigan
authors.forename: Helen M
authors.initials: HM
authors.lastname: Pettinati
mesh_terms: D000328:Adult; D000367:Age Factors; D000437:Alcoholism / Q000145:classification* / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000627:therapeutic use*; D013695:Temperance / Q000145:classification
chemical_list: D009271:Naltrexone